Communiqués Cyclerion Therapeutics, Inc.

Actions

CYCN

US23255M2044

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
2,67 ^USD	-2,91 %		-9,80 %	-20,30 %

07/05	Cyclerion Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
05/03	Cyclerion Therapeutics, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cyclerion Appoints Regina Graul, Ph.D., as President	04/12	AQ
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator	01/12	AQ
Cyclerion Therapeutics, Inc. - Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets	01/08/23	AQ
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets	31/07/23	AQ
CYCLERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	01/06/23	AQ
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement	01/06/23	AQ
Cyclerion Therapeutics : Private Placement - Form 8-K	25/05/23	PU
CYCLERION THERAPEUTICS, INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	25/05/23	AQ
Cyclerion Announces Reverse Stock Split	15/05/23	GL
CYCLERION THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	12/05/23	AQ
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results	12/05/23	GL
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018	12/05/23	GL
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018	12/05/23	AQ
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results	12/05/23	AQ
CYCLERION THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	03/04/23	AQ
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement	03/04/23	GL
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement	03/04/23	GL
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases	27/03/23	GL
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases	27/03/23	AQ
CYCLERION THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	22/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cyclerion Therapeutics, Inc.

Actions

CYCN

US23255M2044

Communiqués

Filtres